CA9 and cancer: CA IX-specific therapeutic modalities in cancer treatment are: monoclonal antibodies directed at the PG-like domain, as cG250 [152], or targeted against its catalytic domain [153-155], small molecule inhibitors [27, 29], and compounds based on sulfonamide/sulfamates and coumarins [156, 157].